3.238.174.191
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

FDA Alerts

FDA approves tralokinumab for moderate-to-severe atopic dermatitis in pediatric patients

The U.S. Food and Drug Administration has expanded the approval of Adbry (tralokinumab-ldrm) to include pediatric patients aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, according to a press release. Tralokinumab is the...

Read More
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-